

Special Issue

Prebiotics and Probiotics for Health Promotion

Message from the Guest Editors

In recent years, there has been an increased interest in the scientific community concerning the microbiota and its relationship with health and disease. Studies regarding the therapeutic potential of restoring dysbiosis as a treatment for common diseases have shown that the administration of prebiotics and probiotics, in combination or separately, is both simple and accessible. Many researchers have demonstrated the effectiveness of pre- and pro-biotics in promoting health or treating certain morbidities (i.e., COVID-19, *H. pylori* infection, vaginosis, etc.); however, concerns have been raised regarding the possible risks of administering probiotics. Prebiotics are simple nutrients that, when degraded by the gut microbiota, produce metabolic molecules that act locally, regulating the microbial communities, or can enter into the bloodstream, reaching distant tissues and affecting their physiology. This Special Issue aims to promote the research and discussion regarding the current knowledge of probiotics/prebiotics, their potential clinical applications, and their possible side effects.

Guest Editors

Prof. Dr. Luigi Santacroce

Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy

Dr. Lucrezia Bottalico

Polypheno Academic Spin Off, University of Bari "Aldo Moro", 70121 Bari, Italy

Deadline for manuscript submissions

closed (15 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/123337

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).